JPRN-UMIN000043767尚未招募未知
agoya University Esophageal Cancer CRT+/-PDT Prognostic Study - NEC2P2 Study
agoya University0 个研究点目标入组 150 人开始时间: 2021年7月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 99years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Women who are pregnant, may become pregnant (intentionally), or are breastfeeding. Men who wish their partner to become pregnant. 2) Patients with concomitant psychosis or psychiatric symptoms that would make it difficult to participate in the study. 3) Patients with active bacterial and fungal infections (fever of 38 degrees or higher, and bacterial infection documented by imaging or bacteriological examination. (Local infections that do not affect the systemic condition are excluded. 4) Patients with interstitial pneumonia, pulmonary fibrosis, or severe emphysema. 5) History of myocardial infarction or unstable angina within 6 months of enrollment. 6) Patients with poorly controlled valvular disease, dilated cardiomyopathy, or hypertrophic cardiomyopathy. 7) Other patients who are judged by the physician in charge to be unable to tolerate the treatment prescribed in this study.
研究者
相似试验
已完成
不适用
For advanced or recurrent esophageal cancer Of combination therapy - docetaxel-cisplatin-5 fluorouracil phase I/II trialAdvanced or recurrent esophageal cancerJPRN-UMIN000014625gifu University30
已完成
不适用
Study of treatment for esophageal cancerEsophageal cancerJPRN-UMIN000040909Graduate School of Medical Sciences,Kyushu University26
进行中（未招募）
1 期
Phase II trial in inoperable œsophageal cancer evaluating the feasibility of the combination of definitive chemoradiation with the immune checkpoint blockers Nivolumab +/- Ipilimumab (CRUCIAL)oesophageal squamous cell carcinoma and oeasophageal adenocarcinomaMedDRA version: 20.0Level: PTClassification code 10061534Term: Oesophageal squamous cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10030137Term: Oesophageal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000053-53-ESEuropean Organisation for Research and Treatment of Cancer130
进行中（未招募）
1 期
Phase II trial in inoperable œsophageal cancer evaluating the feasibility of the combination of definitive chemoradiation with the immune checkpoint blockers Nivolumab +/- Ipilimumab (CRUCIAL)EUCTR2018-000053-53-DEEuropean Organisation for Research and Treatment of Cancer130
已完成
不适用
Patients’ preferences for esophageal cancer screening strategiesNL-OMON25816Radboud university medical center400